Affinity Asset Advisors LLC purchased a new stake in NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 37,000 shares of the company’s stock, valued at approximately $68,000.
Other large investors also recently modified their holdings of the company. Clear Street LLC bought a new position in NewAmsterdam Pharma during the 1st quarter worth $32,000. Exos TFP Holdings LLC bought a new position in NewAmsterdam Pharma during the 4th quarter worth $119,000. RA Capital Management L.P. bought a new position in NewAmsterdam Pharma during the 4th quarter worth $289,000. EcoR1 Capital LLC bought a new position in NewAmsterdam Pharma during the 4th quarter worth $727,000. Finally, Highbridge Capital Management LLC raised its position in NewAmsterdam Pharma by 4.0% during the 1st quarter. Highbridge Capital Management LLC now owns 733,327 shares of the company’s stock worth $1,357,000 after purchasing an additional 27,975 shares during the last quarter.
NewAmsterdam Pharma Stock Performance
Shares of NAMSW stock traded up $0.10 during mid-day trading on Monday, hitting $1.90. The company’s stock had a trading volume of 74,926 shares, compared to its average volume of 20,703. The company’s fifty day simple moving average is $1.97 and its 200-day simple moving average is $2.05. NewAmsterdam Pharma has a 52 week low of $0.46 and a 52 week high of $3.62.
NewAmsterdam Pharma Profile
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on research and development of transformative therapies for metabolic diseases and Alzheimer's disease. The company develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which transports cholesterol from high-density lipoprotein cholesterol (HDL-C) to low-density lipoprotein cholesterol (LDL-C).
Read More
- Five stocks we like better than NewAmsterdam Pharma
- How Can Investors Use the Dogs of the Dow Strategy?
- An Electrifying New Upgrade for Tesla Leads the Market Higher
- 5 Top Rated Dividend Stocks to Consider
- Oil Jumps, 2 Plastic Stocks About To Become Value Plays
- Consumer Staples Stocks, Explained
- The Top 5 Analysts Calls in September
Want to see what other hedge funds are holding NAMSW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report).
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
